Three board members of asthma fighter Respiri have resigned just a day before the company’s annual general meeting.

Respiri (ASX:RSH) owns what it calls “the world’s first digital wheeze detection and measurement technology” that it hopes will allow the world’s estimate 330 million asthma sufferers to live easier lives.

Today it told investors that non-executive chairman Mark Ziirsen and non-executive directors Brendan Mason and Thomas Duthy have resigned.

Mr Ziirsen was only appointed as chairman back in June, while both he and Mr Mason joined the board only in May.

The company is holding its annual general meeting tomorrow November 28.

A month ago, when the AGM date was announced, Messrs Ziirsen, Mason and Duthy were all seeking re-election.

Stockhead has reached out to Respiri to ask about the circumstances behind the resignations.

Respiri shares (ASX:RSH) over the past year.


Ross Blair-Holt and Professor Bruce Thompson have replaced the latter two as new non-executive directors.

Mr Blair-Holt is chief of Bruce Mathieson Group, which is a cornerstone investor in Respiri, and he has been on the board before.

Prof Thompson currently serves as chairman of the company’s Australian Medical and Scientific Advisory Board.

Last year, Respiri hired former Pfizer exec Mario Gattino as CEO.